Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity
top of page
Browse by category
Search
Eli Lilly and Company has announced positive topline results from the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide...
Nerve stimulation for sleep apnoea less effective for people with higher BMIs
Hypoglossal nerve stimulation (HGNS) treatment for obstructive sleep apnoea (OSA) drops significantly as a patient's weight rises above a...
FDA reviewing ProSomnus’ EVO medical device for severe OSA
The FDA has accepted, and is in the process of reviewing, the ProSomnus’ premarket notification for its ProSomnus EVO precision medical...
ProSomnus non-inferior to CPAP therapy for the treatment of moderate to severe OSA
The First Line Obstructive Sleep Apnea Treatment study (FLOSAT) clinical trial assessing ProSomnus, a CPAP alternative for the treatment...
Increased cardiovascular risks for people with obstructive sleep apnoea
Researchers have found that people with have an increased cardiovascular risk due to reduced blood oxygen levels, largely explained by...
Obstructive sleep apnoea could directly cause early cognitive decline
Researchers from the UK, Germany, and Australia have shown for the first time that obstructive sleep apnoea (OSA) in middle-aged men can...
Guy’s and St Thomas’ first in the UK to provide new sleep apnoea treatment
Guy’s and St Thomas’ has become the first NHS trust in the UK to use a pioneering implant device to treat severe sleep apnoea....
Browse by tag
bottom of page